Recombinant Human ULBP3 protein (rFc Tag) (HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg2810

---

Validation Data Gallery

• 

  Purity of Recombinant Human ULBP3 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human ULBP3 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human ULBP3 protein His32-Pro216 (Accession# Q9BZM4) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 79465
• Accession: Q9BZM4
• PredictedSize: 48.1 kDa
• SDS-PAGE: 48-60 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

ULBP3 (UL16 binding protein-3), a class 1 major histocompatibility complex-like (MHC-like) molecule and member of the family of ligands of the killer cell lectin-like receptor subfamily K member 1 (NKG2D). This protein plays a crucial role in the immune response against tumors, as it can stimulate antitumor responses and recruit NK cells, NK1.1+ T cells, and T cells to tumor. ULBP3 is expressed by a variety of leukemias, carcinomas, melanomas, and other tumor cell lines, and its expression has been correlated with improved survival in cancer patients.

References:

1.Wirsching HG, et al. (2019). JCI Insight. 4 (13)
2.Mao C, et al. (2012). Hybridoma (Larchmt). 31 (3):203-8. 
3.Sutherland CL,et al.(2006) Blood. 108 (4):1313-9.